Objectives: A previous study on 12 in vitro-selected azithromycin-resistant Legionella pneumophila lineages showed that ribosomal mutations were major macrolide resistance determinants. In addition to these mechanisms that have been well described in many species, mutations upstream of lpeAB operon, homologous to acrAB in Escherichia coli, were identified in two lineages. In this study, we investigated the role of LpeAB and of these mutations in macrolide resistance of L. pneumophila.
Introduction
Legionella pneumophila (Lp) is responsible for .90% of Legionnaires' disease cases. 1, 2 International guidelines recommend macrolides (particularly azithromycin) or fluoroquinolones as first-line therapy for treating this potentially severe pneumonia. [3] [4] [5] No macrolide-resistant Lp strain has ever been isolated and susceptibility testing of clinical Lp strains is rarely performed. However, therapeutic failures have been described despite adequate therapy. 6 These might result from undetected macrolide resistance since resistant Lp can easily be selected in vitro. 7 This hypothesis is reinforced by the recent description of the first cases of Legionnaires' disease related to a fluoroquinolone-resistant Lp strain. 8, 9 To characterize macrolide resistance determinants in Lp, we previously selected 12 independent lineages from a common ancestral Lp Paris strain to high-level resistance by serial passages under increasing erythromycin or azithromycin concentrations. 10 WGS of these 12 evolved clones identified mutations in genes encoding 23S ribosomal RNA (rRNA), L4 and/or L22 ribosomal proteins in all lineages. Reconstructing these mutations in the ancestral Lp strain proved the link between these mutations and macrolide resistance.
In two of the six azithromycin-selected lineages (Azi 1 and Azi 3), mutations were also discovered in the upstream region of the lpp2879-lpp2880 operon. A double substitution (CA to GG) occurred in the ribosomal binding site (RBS) in one lineage (Azi 3) and a T to A substitution one nucleotide downstream of the promoter in the other (Azi 1) according to Lp Paris strain sequencing and annotation performed by Cazalet et al.
11 Lpp2879-Lpp2880 is homologous to Escherichia coli AcrAB, forming with TolC a tripartite efflux pump of the resistance-nodulation-division (RND) family, which are major antibiotic resistance determinants in Gram-negative bacteria. Because of this homology with acrAB we chose to rename lpp2879-lpp2880 as lpeAB.
This study investigated the role of LpeAB in the macrolide resistance of the Lp Paris strain and demonstrated the roles: (i) of the proteins themselves; (ii) of point mutations upstream of the encoding gene sequence observed in the two resistant clones; and (iii) of sub-inhibitory macrolide concentrations on protein expression.
Materials and methods

Bacterial strains and culture media
The reference strain Lp serogroup 1 Paris (CIP 107629T) was used as the WT strain. Lp was grown in N-(2-acetamido)-2-aminoethanesulfonic acidbuffered yeast extract broth at 37 C without agitation in an aerobic atmosphere or on buffered charcoal yeast extract (BCYE) agar plates (Oxoid) at 35 C in an aerobic atmosphere. The procedures using E. coli were performed on strain MG1655 grown in LB or on LB-agar plates at 37 C in an aerobic atmosphere.
Antibiotics and toxic components
The following antimicrobial agents were tested: erythromycin, azithromycin, clarithromycin, clindamycin and rifampicin (Sigma-Aldrich); spiramycin and pristinamycin (Sanofi); and ciprofloxacin (Bayer).
Solutions of SDS (Euromedex), methylene blue (Société chimique Pointet Girard), rhodamine 6G (Sigma-Aldrich), crystal violet (Merck), sodium desoxycholate (Sigma-Aldrich) and ethidium bromide (EtBr; Carl Roth) were prepared in sterile water.
Construction of an Lp DlpeAB mutant
An lpeAB knock-out strain was constructed from the WT strain by a twostep homologous recombination method. Two kb flanking regions located upstream and downstream of lpeAB were amplified by PCR using d1S, d1RJ1, d2SJ1 and d2R primers (Table 1) . A resistance cassette was inserted between these two regions by double-joint PCR. 13 This cassette carried a kanamycin resistance gene and the mazF gene encoding an endoribonuclease placed under the control of an IPTG-inducible expression system used as a counter-selectable marker.
14 Another mutant DNA fragment in which the two lpeAB flanking regions were simply bound together was constructed.
The WT chromosomal sequence was replaced by the mutant DNA fragment that contains the resistance cassette by induction of competence for natural transformation in an Lp Paris strain as previously described. 15 The clones that grew on BCYE agar plates containing kanamycin 15 mg/L but did not grow on IPTG-supplemented BCYE plates (0.5 mM) were transformed with the second mutant DNA fragment (containing only lpeAB flanking regions) according to the same procedure. Recombinant clones that grew on IPTG-supplemented BCYE plates were analysed by PCR and sequencing to confirm the deletion of lpeAB and the loss of the resistance cassette.
Complementation with lpeAB
A DNA fragment containing lpeAB was obtained from the WT strain by PCR with the primers 2879SNheI and 2880RSalI (Table 1) , creating NheI and SalI restriction sites upstream and downstream of the genes, respectively. It was then digested by the restriction endonucleases NheI and SalI (New England Biolabs, Evry, France). The plasmid pXDC50 16 carrying a chloramphenicol resistance gene was cut with the restriction enzymes XbaI (NheI compatible) and SalI. Plasmid pXDC50_lpeAB was constructed by cloning the lpeAB genes into these sites, under the control of the pTac promoter Massip et al.
(IPTG inducible). The construct was verified by sequencing. Both the Lp ancestral Paris strain and DlpeAB mutant strain were transformed with pXDC50_lpeAB. After electroporation (2500 V, 25 lF, 100 X), the complemented bacteria were selected on BCYE agar plates containing 5 mg/L chloramphenicol.
MIC determination
The MICs of antibiotics (erythromycin, clarithromycin, azithromycin, spiramycin, clindamycin, pristinamycin, ciprofloxacin, rifampicin) and toxic components (SDS, methylene blue, rhodamine 6G, crystal violet, sodium desoxycholate, EtBr) were determined in triplicate for the WT, the DlpeAB and the complemented strains as previously described. 17 Briefly, bacterial suspensions with concentrations of 5.10 5 cfu/mL were dispensed in 96-well microtitre plates (160 lL per well). For strains harbouring plasmids pXDC50 or pXDC50_lpeAB, growth media were supplemented with chloramphenicol (5 mg/L) and IPTG (2 mM). Antimicrobial agents or toxic components were added with increasing 2-fold concentrations (40 lL per well). The MICs were determined as the lowest antibiotic concentrations that inhibited visible bacterial growth after a 72 h incubation at 35 C in an aerobic atmosphere.
Dynamics of substitution observed in the upstream region of lpeAB
The dynamics of mutation involved in Azi 1 and Azi 3 lineages were determined retrospectively from the bacterial mixtures frozen during the evolution procedure using VerifPromS and VerifPromR primers (Table 1) and PrimeSTAR Max DNA polymerase TaKaRa (Clontech). GATC Biotech performed the sequencing of PCR products. Sequence alignments were performed by Seaview software 18 in comparison with the Lp Paris strain reference sequence.
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The proportions of sub-populations mutated in the upstream region of the lpeAB operon were determined in Azi 1 and Azi 3 final bacterial mixtures by NGS deep sequencing of the mutated region. First, the region was amplified using NGS_F and NGS_R primers by Phusion V R High-Fidelity DNA polymerase (New England Biolabs). The amplified products were purified by ultrafiltration (Merck Millipore) and quantified using the DNA High Sensitivity assay carried out on a Labchip GX Touch (PerkinElmer). Amplicon libraries were then generated using the AB builder system and the Ion Plus Fragment library kit according to the manufacturer's instructions (Thermo Fisher Scientific). The library clonal amplification was carried out by emulsion PCR using the Ion OneTouch System and Ion PGM Template OT2 Hi-Q kit (Thermo Fisher Scientific). Template-positive Ion Sphere Particles were then enriched using the Ion OneTouch ES system and purified Ion Sphere particles were loaded on an Ion 316 Chip v2 (Thermo Fisher Scientific). Sequencing was carried out on Ion PGM (Thermo Fisher Scientific). Reads were mapped against the reference sequences extracted from the genome (NC_006368). Mapping and variant calling were performed using the Torrent Suite 5.0.2.
Translational fusion experiments using GFP as a reporter
Four DNA fragments containing the upstream region of lpeAB were amplified: a WT DNA fragment using Lp Paris genomic DNA as the template, a fragment with the mutation T3280761A one nucleotide downstream of the lpeAB promoter using Azi 1 DNA, a fragment with the double substitution CA3280785-6GG in lpeAB RBS using the Azi 3 DNA, and a fragment with both Azi 1 and Azi 3 mutations. The forward primer Prom2879sphIS created a SphI restriction site at the end of cspC ( Table 1 ). The 5 0 -sequence of gfp gene was amplified by PCR from the plasmid pX3. 19 Four joint PCR amplifications were conducted to link the fragments containing the WT or the three mutated upstream regions of lpeAB with the fragment containing the beginning of the gfp gene. The synthesized DNA fragments and the plasmid pX3 were digested with SphI and XhoI restriction enzymes. Plasmids (namely pWT, pProm, pRBS and pProm_RBS, respectively) were constructed by cloning the fragments into plasmid pX3. The WT strain was transformed with each of the four plasmids.
Bacterial suspensions of the transformed strains were prepared in chloramphenicol-supplemented buffered yeast extract broth (5 mg/L) at an OD 600 nm (OD 600 ) of 0.1 and dispensed in a 96-well microtitre plate (200 lL/well). The plates were incubated in the automated InfinitePro plate reader (TECAN, Lyon, France) for 35 h at 37 C under shaking. The intensity of fluorescence emitted by GFP (k excitation : 485 nm, k emission : 535 nm) and the OD 600 were measured every 15 min. The same experiment was conducted adding sub-inhibitory concentrations of erythromycin or azithromycin (1/8 and 1/16 of MIC, 0.031 or 0.016 mg/L, respectively). Each experimental condition was tested in triplicate.
Statistical analysis
R software (version 3.1.1) was used for statistical analysis. The MICs of the WT, DlpeAB and complemented strains were first compared using the Kruskal-Wallis test. If the MICs were significantly different for the three strains, we used the Wilcoxon-Mann-Whitney tests to determine whether the MICs of the DlpeAB mutant were lower than the MICs of the WT and the complemented strains. These statistical tests were chosen because they can be applied to data with normal or unknown distribution.
Results
Role of LpeAB in Lp Paris susceptibility to antibiotics and toxic compounds
The MICs of the WT, DlpeAB and complemented strains were significantly different for erythromycin, azithromycin and spiramycin Impact of mutations and macrolide sub-inhibitory concentrations on protein expression GFP expression was increased in strains carrying the plasmids pRBS [maximum 3000 relative fluorescence units (RFU)] and pProm (maximum 1700 RFU) in comparison with the strain carrying the plasmid pWT (maximum 400 RFU; Figure 2 ). An additive effect was observed in the strain carrying mutations in both the promoter and the RBS (plasmid pProm_RBS) since GFP expression was further increased up to 4700 RFU. Carrying either mutant or WT plasmids LpeAB macrolides efflux pump JAC had no impact on the growth of Lp Paris strain during the time of experiment (Figure 2) .
Although the addition of erythromycin in the growth medium slightly inhibited bacterial growth (Figure 3) , GFP expression was increased by sub-inhibitory concentrations of erythromycin (1/8 and 1/16 of MIC) in a concentration-dependent manner in strains carrying the plasmids pWT, pProm, pRBS or pProm_RBS (Figure 3) . Similar results were obtained using sub-inhibitory concentrations of azithromycin (data not shown).
Dynamics of substitution
In Azi 1 lineage, sequencing of the region upstream of lpeAB from intermediate bacterial populations at different steps of the selection procedure revealed that the T3280761A substitution occurred in a late step (19th of the 20 passages) during the resistance selection process. 10 Deep sequencing of the corresponding PCR products demonstrated that the mutation was carried by only 20% and 48% of the populations of the 19th and the 20th passages, respectively. However, this mutation was not associated with an increased azithromycin MIC.
In Azi 3 lineage, the CA3280785-6GG double substitution in the RBS appeared at the 13th passage and was not associated with an additional increase in azithromycin MIC. Next-generation sequencing (NGS) data obtained from the final population revealed that the CA3280785-6GG double substitution was carried by the main population present in the sample.
Discussion
In this study, by a deletion/complementation approach, we first showed that lpeAB genes were involved in a moderate level of macrolide resistance in L. pneumophila, with a 4-(erythromycin) to 16-fold (azithromycin) decrease in macrolide MICs when these genes were deleted. Translational fusion experiments showed that the two mutations observed upstream of the encoding gene sequence in azithromycin-resistant lineages (a point mutation one nucleotide downstream of lpeAB promoter and a double substitution in lpeAB RBS) increased the protein expression, which would lead to an increased expression of the efflux pump. Finally, we showed that macrolide sub-inhibitory concentrations themselves also induced an enhancement of protein expression. The two mutations upstream of the lpeAB gene sequence were detected in a previous work in which we selected macrolideresistant lineages and demonstrated that mutations in genes encoding 23S rRNA or L4 and L22 ribosomal proteins were major macrolide resistance determinants in Lp. 10 These ribosomal mechanisms had been well described in other respiratory pathogens such as Mycoplasma pneumoniae 20 and Haemophilus influenzae.
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In our study, the WGS of the resistant clones allowed a nontargeted investigation of resistance mechanisms. LpeAB genes are organized as an operon and are homologous to E. coli acrAB genes. The periplasmic protein AcrA, the inner membrane protein AcrB, and the outer membrane protein TolC form a tripartite efflux pump of the RND family. 12 Such efflux pumps are widely distributed in Gram-negative bacteria and contribute to resistance against potentially toxic components such as dyes, surfactants and antibiotics. 12, 22 They are also macrolide resistance determinants in many Gram-negative species such as Campylobacter jejuni, 23 Neisseria gonorrhoeae 24 and H. influenzae.
Our study was conducted on an Lp Paris strain belonging to ST1 because of its clinical relevance. Paris strain is responsible for sporadic and epidemic cases of Legionnaires' disease worldwide and is endemic in Europe, the USA and Japan. 25 The analysis of lpeAB distribution in genome databases shows that these genes are present in a small subset of Lp genomes, most of which correspond with ST1 strains (data not shown). It is notable that all ST1 strains for which genome sequences are available possess lpeAB genes. Among Lp strains, the relative specificity of LpeAB for the ST1 could be correlated to a previous study that found a reduced azithromycin susceptibility of clinical ST1 strains compared with other STs. 26 In this study, 23S rRNA methylase genes, mefA and mefE efflux pump LpeAB macrolides efflux pump JAC genes, erythromycin esterase genes and mutations affecting 23S rRNA, L4 and L22 proteins were screened in ST1 strains but none of them accounted for the reduced azithromycin susceptibility. The 16-fold increase (from 0.5 to 0.031 mg/L) in azithromycin susceptibility in lpeAB knockout Paris strain observed in our study had the same magnitude as the gap described between azithromycin MICs of ST1 strains (0.5-2 mg/L) and other STs (0.0625-0.5 mg/L). 26 Thus, we hypothesized that the LpeAB efflux pump could be responsible for a specific reduced azithromycin susceptibility of all ST1 strains.
Apart from erythromycin, azithromycin and spiramycin, knocking out lpeAB had no impact on susceptibility to other antibiotics or toxic components (EtBr, methylene blue or sodium desoxycholate) that are typical AcrAB-TolC substrates. 27 Unlike most RND efflux pumps, which exhibit a broad substrate specificity, the LpeAB efflux pump may recognize a limited number of substrates; 27 it was notably not involved in the transport of clarithromycin, a macrolide that only differs from erythromycin by an extra methyl moiety. Conversely, erythromycin, azithromycin and spiramycin, which exhibit strong discrepancies as regards the number of atoms in their macrolactone cycle or their amino-sugar substituents, 28 were pumped out of the cell. Therefore, we did not manage to detect a pattern that would define LpeAB substrates. Each RND efflux pump has its own substrate specificity defined by its inner membrane protein. AcrAD-TolC is an example of an RND efflux pump with narrow substrate specificity: it confers high resistance to anionic b-lactams (as opposed to AcrAB-TolC), and no or weak resistance against typical AcrAB substrates. 29 Although typical AcrAB-TolC substrates were screened as potential substrates for the LpeAB efflux pump, we tested a limited number of compounds. This pump may contribute to protecting the bacteria from antibiotics from the soil (erythromycin being naturally synthesized by Streptomyces species), natural or artificial waters, but also from toxic components such as antimicrobial peptides and heavy metals that exist in its hydro-telluric environment. It could also contribute to the Paris strain pathogenicity as in Neisseria meningitidis, which uses the AcrAB-TolC homologue MtrCDE to resist cationic antimicrobial peptides, 30 or in Pseudomonas aeruginosa in which the RND efflux pump MexABOprM participates in quorum sensing. 31 Lp Paris strain infections are associated with a 30.9% mortality rate whereas the overall mortality due to Lp is reported to be 18.6%. 32 The LpeAB efflux pump could partially account for this high pathogenicity towards humans. Further experiments have to be conducted to explore these possible roles of LpeAB proteins.
After having demonstrated the role of LpeAB in the macrolide efflux, we focused on the two mutations detected in the upstream region of lpeAB in macrolide-resistant mutants: a double substitution in the RBS in one lineage and a substitution one nucleotide downstream of the promoter in the second lineage. Translational fusion experiments showed an increase in protein expression due to both mutations, which may reflect an over-synthesis of the efflux pump. Interestingly, they also revealed a higher protein expression in response to erythromycin or azithromycin (data not shown) sub-inhibitory concentrations, for both WT or mutated lpeAB promoting region, suggesting an additional mechanism constitutively present in the Lp Paris strain and directly triggered by macrolides. 33 The regulation mechanisms of RND efflux pumps have been well characterized for the E. coli operon, acrAB. AcrAB expression is under the control of a local repressor AcrR, 34 but also of global regulators (MarA, Rob, SoxS 35 ), and of two-component systems. 36 These three different regulation systems enable E. coli to quickly adapt to environmental changes, with no genomic mutation. Such systems have not been described for regulating LpeAB in Legionella and we did not identify any consensus marbox sequence in the region surrounding the characterized promoter sequence of lpeAB in the Lp Paris strain 11 (data not shown). However, our results clearly indicated that macrolides could naturally act as de-repressors or activators of LpeAB regulators, leading to an increased expression of the efflux pump enabling the Lp Paris strain to better resist to macrolides.
The mutations in the upstream region of lpeAB occurred in the late steps of the selection procedure of Azi 1 and Azi 3 lineages (in which MICs were 256 mg/L) and were not associated with a new increase in azithromycin MICs. These data indicate that these mutations are minor macrolide resistance determinants in comparison to mutations in genes encoding 23S rRNA. Mutations in the upstream region of lpeAB that occurred late on in the selection procedure under high concentrations of macrolides could improve bacterial fitness. Indeed, even if macrolides were inactive because of target alterations, their accumulation in the bacteria could impair cellular machinery. The improved extrusion of this large amount of macrolides could thus confer a selective advantage to the Lp strain Paris. We also hypothesized that the constitutive efflux of macrolides by the LpeAB efflux pump could be a prerequisite for the selection of a highly resistant Lp Paris strain. It would protect the bacteria against macrolides long enough to develop more efficient resistance determinants involving mutations in genes encoding 23S rRNA or ribosomal proteins. In Salmonella enterica serovar Typhimurium, Ricci et al. demonstrated that the selection of ciprofloxacin-resistant mutants was almost impossible without functional AcrB or TolC. 37 For macrolides, a single mutation in the gene encoding L22 ribosomal protein in H. influenzae was not sufficient to confer high-level resistance unless efflux was present. 38 In conclusion, this study showed that the LpeAB are components of an efflux pump, a macrolide resistance determinant in Lp Paris. Macrolide exposure induced LpeAB overproduction potentially leading to decreased macrolide susceptibility. This mechanism enabled Lp to adapt quickly to macrolide pressure without any mutation. In highly azithromycin-resistant L. pneumophila clones, mutations in the upstream region of lpeAB were linked with an increased protein expression. They could be auxiliary resistance mechanisms in addition to highresistance ribosomal determinants. The results of this study warrant further investigations regarding the regulatory mechanisms of the LpeAB efflux pump.
